Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

ODYSSEY OUTCOMES Committees and Investigators; Pierluigi Tricoci; Matthew T Roe; Kenneth W Mahaffey; Steen Hvitfeldt Poulsen; Bent Raungaard; Peter Clemmensen; Lia E Bang; Ole May; Morten Bøttcher; Jens Dahlgaard Hove; Lars Frost; Gunnar Hilmar Gislason; John Larsen; Peter Betton Johansen; Flemming Hald; Jørgen Jeppesen; Tonny Nielsen; Kjeld S. Kristensen; Piotr Maria Walichiewicz; Jens D Lomholdt; Ib C Klausen; Peter Kaiser Nielsen; Flemming Davidsen; Lars Videbaek; Cecile Gache; Emmy Badreddine; Mhamed Bekkouche

doi:10.1056/nejmoa1801174

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

ODYSSEY OUTCOMES Committees and Investigators, Pierluigi Tricoci, Matthew T Roe, Kenneth W Mahaffey, Steen Hvitfeldt Poulsen, Bent Raungaard, Peter Clemmensen, Lia E Bang, Ole May, Morten Bøttcher, Jens Dahlgaard Hove, Lars Frost, Gunnar Hilmar Gislason, John Larsen, Peter Betton Johansen, Flemming Hald, Jørgen Jeppesen, Tonny Nielsen, Kjeld S. Kristensen, Piotr Maria WalichiewiczJens D Lomholdt, Ib C Klausen, Peter Kaiser Nielsen, Flemming Davidsen, Lars Videbaek, Cecile Gache, Emmy Badreddine, Mhamed Bekkouche

Institut for Klinisk Medicin

899 Citationer (Scopus)

Abstract

BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

Originalsprog	Engelsk
Tidsskrift	The New England Journal of Medicine
Vol/bind	379
Udgave nummer	22
Sider (fra-til)	2097-2107
ISSN	0028-4793
DOI	https://doi.org/10.1056/nejmoa1801174
Status	Udgivet - 29 nov. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1056/nejmoa1801174

Coverdale437929-Published.pdfForlagets udgivne version, 455 KB

Citationsformater

ODYSSEY OUTCOMES Committees and Investigators, Tricoci, P., Roe, M. T., Mahaffey, K. W., Poulsen, S. H., Raungaard, B., Clemmensen, P., Bang, L. E., May, O., Bøttcher, M., Hove, J. D., Frost, L., Gislason, G. H., Larsen, J., Johansen, P. B., Hald, F., Jeppesen, J., Nielsen, T., Kristensen, K. S., ... Bekkouche , M. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379(22), 2097-2107. https://doi.org/10.1056/nejmoa1801174

ODYSSEY OUTCOMES Committees and Investigators, Tricoci, P, Roe, MT, Mahaffey, KW, Poulsen, SH, Raungaard, B, Clemmensen, P, Bang, LE, May, O, Bøttcher, M, Hove, JD, Frost, L, Gislason, GH, Larsen, J, Johansen, PB, Hald, F, Jeppesen, J, Nielsen, T, Kristensen, KS, Walichiewicz, PM, Lomholdt, JD, Klausen, IC, Nielsen, PK, Davidsen, F, Videbaek, L, Gache, C, Badreddine, E & Bekkouche , M 2018, 'Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome', The New England Journal of Medicine, bind 379, nr. 22, s. 2097-2107. https://doi.org/10.1056/nejmoa1801174

@article{efb534b7b19e487881333c48c5619e6f,

title = "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome",

abstract = "BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.",

keywords = "Acute Coronary Syndrome/blood, Adult, Aged, Antibodies, Monoclonal/adverse effects, Anticholesteremic Agents/adverse effects, Cardiovascular Diseases/epidemiology, Cholesterol, LDL/blood, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia/complications, Male, Middle Aged, Proprotein Convertase 9/antagonists & inhibitors",

author = "Schwartz, {Gregory G} and Steg, {P Gabriel} and Michael Szarek and Bhatt, {Deepak L} and Bittner, {Vera A} and Rafael Diaz and Edelberg, {Jay M} and Goodman, {Shaun G} and Corinne Hanotin and Harrington, {Robert A} and Jukema, {J Wouter} and Guillaume Lecorps and Mahaffey, {Kenneth W} and Ang{\`e}le Moryusef and Robert Pordy and Kirby Quintero and Roe, {Matthew T} and Sasiela, {William J} and Jean-Fran{\c c}ois Tamby and Pierluigi Tricoci and White, {Harvey D} and Zeiher, {Andreas M} and {ODYSSEY OUTCOMES Committees and Investigators} and Pierluigi Tricoci and Roe, {Matthew T} and Mahaffey, {Kenneth W} and Poulsen, {Steen Hvitfeldt} and Bent Raungaard and Peter Clemmensen and Bang, {Lia E} and Ole May and Morten B{\o}ttcher and Hove, {Jens Dahlgaard} and Lars Frost and Gislason, {Gunnar Hilmar} and John Larsen and Johansen, {Peter Betton} and Flemming Hald and J{\o}rgen Jeppesen and Tonny Nielsen and Kristensen, {Kjeld S.} and Walichiewicz, {Piotr Maria} and Lomholdt, {Jens D} and Klausen, {Ib C} and Nielsen, {Peter Kaiser} and Flemming Davidsen and Lars Videbaek and Cecile Gache and Emmy Badreddine and Mhamed Bekkouche",

year = "2018",

month = nov,

day = "29",

doi = "10.1056/nejmoa1801174",

language = "English",

volume = "379",

pages = "2097--2107",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

AU - Schwartz, Gregory G

AU - Steg, P Gabriel

AU - Szarek, Michael

AU - Bhatt, Deepak L

AU - Bittner, Vera A

AU - Diaz, Rafael

AU - Edelberg, Jay M

AU - Goodman, Shaun G

AU - Hanotin, Corinne

AU - Harrington, Robert A

AU - Jukema, J Wouter

AU - Lecorps, Guillaume

AU - Mahaffey, Kenneth W

AU - Moryusef, Angèle

AU - Pordy, Robert

AU - Quintero, Kirby

AU - Roe, Matthew T

AU - Sasiela, William J

AU - Tamby, Jean-François

AU - Tricoci, Pierluigi

AU - White, Harvey D

AU - Zeiher, Andreas M

AU - ODYSSEY OUTCOMES Committees and Investigators

AU - Tricoci, Pierluigi

AU - Roe, Matthew T

AU - Mahaffey, Kenneth W

AU - Poulsen, Steen Hvitfeldt

AU - Raungaard, Bent

AU - Clemmensen, Peter

AU - Bang, Lia E

AU - May, Ole

AU - Bøttcher, Morten

AU - Hove, Jens Dahlgaard

AU - Frost, Lars

AU - Gislason, Gunnar Hilmar

AU - Larsen, John

AU - Johansen, Peter Betton

AU - Hald, Flemming

AU - Jeppesen, Jørgen

AU - Nielsen, Tonny

AU - Kristensen, Kjeld S.

AU - Walichiewicz, Piotr Maria

AU - Lomholdt, Jens D

AU - Klausen, Ib C

AU - Nielsen, Peter Kaiser

AU - Davidsen, Flemming

AU - Videbaek, Lars

AU - Gache, Cecile

AU - Badreddine, Emmy

AU - Bekkouche , Mhamed

PY - 2018/11/29

Y1 - 2018/11/29

N2 - BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

AB - BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-highdensity lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS Among patients who had a previous acute coronary syndrome and who were receiving highintensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo.

KW - Acute Coronary Syndrome/blood

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal/adverse effects

KW - Anticholesteremic Agents/adverse effects

KW - Cardiovascular Diseases/epidemiology

KW - Cholesterol, LDL/blood

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hypercholesterolemia/complications

KW - Male

KW - Middle Aged

KW - Proprotein Convertase 9/antagonists & inhibitors

U2 - 10.1056/nejmoa1801174

DO - 10.1056/nejmoa1801174

M3 - Journal article

C2 - 30403574

SN - 0028-4793

VL - 379

SP - 2097

EP - 2107

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 22

ER -

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater